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Abstract
Objective: To investigate the association between common transforming growth factor beta (TGF-b) single nucleotide
polymorphisms (SNP) and significant complications of coronary heart disease (CHD).
Method: We performed a meta-analysis of published case-control studies assessing the association of TGF-b SNPs with a
range of CHD complications. A random effects model was used to calculate odds ratios and confidence intervals. Analyses
were conducted for additive, dominant and recessive modes of inheritance.
Results: Six studies involving 5535 cases and 2970 controls examining the association of common SNPs in TGF-b1 with CHD
were identified. Applying a dominant model of inheritance, three TGF-b1 SNPs were significantly associated with CHD
complications: The T alleles of rs1800469 (OR=1.125, 95% CI 1.016–1.247, p=0.031) and rs1800470 (OR=1.146, 95% CI
1.026–1.279, p=0.021); and the C allele of rs1800471 (OR=1.207, 95% CI 1.037–1.406, p=0.021).
Conclusion: This meta-analysis suggests that common genetic polymorphisms in TGF-b1 are associated with complications
of CHD.
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Introduction
Coronary heart disease (CHD) is the leading cause of mortality
in the western world. In the U.S.A. CHD is responsible for 1 in
every 6 deaths and is estimated to cost over US$177.5 billion per
annum. [1] Early stage CHD is asymptomatic, but advanced
disease is associated with severe complications including myocar-
dial infarction, heart failure, unstable angina and sudden cardiac
arrest. [2] Well defined risk factors for CHD include smoking,
diabetes, hypertension, dyslipidaemia, male gender and age. A
family history of CHD also confers significant risk, demonstrated
by an eightfold increase in monozygotic twins and a fourfold
increase in dizygotic twins of affected individuals. [3] The genetic
mechanisms underlying CHD predisposition are poorly under-
stood despite recent findings from genome-wide association studies
(GWAS) (discussed in detail by Patel et al. (2011)). [4].
Data from independent gene studies suggest a putative role for
TGF-b signalling in CHD. [5,6] A range of potentially athero-
protective roles have been described for the TGF-b isoforms,
favouring a stable fibrous plaque over an unstable inflammatory
plaque. In vitro studies have shown TGF-b1 to upregulate
extracellular matrix (ECM) production, inhibit vascular smooth
muscle cell proliferation and impair division and migration of
endothelial cells. [7] Additionally, TGF-b1 modulates the local
inflammatoryresponsebydown-regulatingexpressionofendothelial
adhesion molecules, inhibiting foam cell formation and impeding
proliferation of CD4 and CD8 T lymphocytes. [7] Dysregulation of
TGF-bsignallingresultingfromgeneticmutations,particularlysingle
nucleotidepolymorphisms(SNPs),withincomponentsoftheTGF-b
signallingpathwayhavebeenlinkedtoanincreasedriskofdeveloping
common vascular diseases. [8,9] Some but not all studies suggest a
positive association between CHD and several SNPs within genes
encoding TGF-b cytokines. [5,6,10,11,12,13] Given the current
discordanceinpublishedstudies,theinvolvementofTGF-bSNPsin
CHD pathogenesis remains unclear. Accordingly, we conducted a
meta-analysis combining publically available data with the aim of
clarifying whether TGF-b SNPs are associated with clinically
significant complications ofCHD.
Methods
Search Strategy
A search strategy was devised to identify published studies
assessing the association of TGF-b1, TGF-b2 and TGF-b3 SNPs
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37878with end-stage complications of CHD. The search followed the
guidelines of the 2009 preferred reporting items for systematic
reviews and meta-analysis (PRISMA) statement and was under-
taken in two stages. [14] Initially, the MEDLINE database was
searched using the terms ‘‘transforming growth factor’’ or ‘‘TGF’’
and ‘‘SNP’’ or ‘‘polymorphism’’ and ‘‘coronary heart disease’’,
limits human. Focused searches were also undertaken as above,
including ‘‘myocardial infarction’’, ‘‘unstable angina’’, ‘‘heart
failure’’ or ‘‘sudden cardiac arrest’’ as specific complications of
CHD. Hand-searching of references and use of the related articles
function in Pubmed was performed to identify any additional
studies. Finally, following the recommendations of Stern and
Simes (1997), we minimized the possibility of publication bias in
our meta-analysis by searching the National Institute of Health
clinical trials registry (http://clinicaltrials.gov/) using original
search terms to identify unpublished studies eligible for inclusion
in the current analysis. These searches were restricted to studies
that started before 2010 to avoid the problem of the delayed
publication of studies with negative results and included both large
and small scale investigations. [15].
Study Selection
Studies included were case-control investigations comparing the
association of TGF-b1, TGF-b2 and TGF-b3 SNPs with clinical
endpoints of CHD. Studies in which subjects did not have
documented symptoms and diagnostic evidence of CHD were
excluded. Studies which included cases with mixed types of heart
disease, such as congenital heart disease, were excluded. Animal
studies were excluded. Abstracts were initially screened by the
primary author (DM). If a decision could not be made regarding
inclusion, the full text of the article was examined.
Data Extraction
The following data were independently extracted from selected
studies by two authors (DM & JM) using a standardised data
extraction form: 1) study design; 2) number of participants in case
and control groups; 3) patient characteristics of each group; 4)
method of screening for CHD; 5) SNP(s) assessed; and 6) odds
ratio (OR) and 95% confidence interval for association with CHD.
Limitations or biases stated by the authors of each study were also
recorded. SNP annotation was standardised using RS numbers as
stated by the publishing authors. If this detail was not provided,
RS numbers were assigned using the dbSNP resource on the
NCBI server where possible. [16] After completion of the data
extraction, the two reviewers compared their findings and resolved
any disagreements at a consensus meeting. The data extraction
prototol utilised in this study, and proof of compliance with
PRISMA guidelines are provided as Text S1 and Table S1
respectively.
Quantitative Data Synthesis
Combined unadjusted ORs for the association of TGF-b
SNPs with CHD complications were generated using additive,
dominant and recessive inheritance under a random effects
model. For the rs1800469, rs1800470 and rs1800471 SNPs
publication bias was assessed using funnel plots. Heterogeneity
analysis was performed using the Cochran Q test and I2 index.
Sensitivity analyses were performed using the one-study remove
approach to assess the impact of each study on the combined
effect as previously described. [9] All computations were
performed using the Comprehensive Meta Analysis v2 software
package (Biostat, Inc.).
Results
Flow of Included Studies
From 45 publications identified by initial data searches, 10
studies fulfilled inclusion criteria for the systematic review and
were selected for further assessment (Figure 1). The full texts of
these 10 studies were evaluated, after which 2 articles were
excluded. One study was not included as it assessed patients only
with end stage renal disease. [17] Furthermore, the case
population included patients with non-cardiac atherosclerotic
disease. [17] The second study assessed the prevalence of a
selected TGF-b2 SNP in CHD patients, however, the SNP that
was assessed was not named. [10] The remaining 8 studies
focussed solely on TGF-b1 SNPs in cases and controls (Table 1).
Furthermore the study of Sie et al. (2006) utilised a prospective
cohort design and that of Manginas et al. (2008) did not include a
control group with which to compare genotype distributions. [5,6]
Accordingly, these two studies were also excluded, leaving 6
independent case-control investigations in the current meta-
analysis (Figure 1).
Study Characteristics
A collective total of 8,505 patients were included across the 6
studies (cases n=5535, controls n=2970). Five investigations were
conducted in patients from a Western European background and
one study was conducted using Japanese recruits. [18] Population
sizes of the independent studies ranged from 238 to 4868
participants. Cases included patients with myocardial infarction
(4 studies), ischemic heart failure (1 study) or patients with
angiographically-proven CHD (1 study). [13] Three studies
utilised coronary angiography to confirm a positive diagnosis of
CHD whereas two studies relied on the World Health Organi-
sation diagnostic criteria for MI, employing clinical history, ECG
and cardiac biomarkers. Likewise, there was also considerable
inter-study variation in screening of controls, with only two studies
utilising coronary angiography to confirm a negative diagnosis of
CHD. [13,19] Common CHD risk factors for cases and controls
are shown in Table 1. With the exception of age and gender,
studies did not match cases and controls for conventional CHD
risk factors. Moreover, the distribution of risk factors was not
uniformly reported across studies and two studies failed to
document the occurrence of environmental risk factors. [12,19]
Reported data suggested that CHD populations demonstrated a
higher prevalence of hypertension, smoking, diabetes and
dyslipidaemia. Only two investigations sub-divided population
groups by sex. [18,19].
Five TGF-b1 SNPs (rs1800468, rs1800469, rs1800471,
rs1800472, rs1800470) were investigated in the included studies.
The rs1800468 (G-800A) and rs1800469 (C-509T) SNPs are
located in the gene promoter, whereas the rs1800470 (Leu10R
Pro), rs1800471 (Arg25RPro) and rs1800472 (Thr263RIle)
polymorphisms are located in coding regions (Table 2). Cambien
et al. (1996) assessed two additional SNPs which were not included
in the meta-analysis. [20] The rs1800820 SNP (C-988A) was
present in only 2 of the 1192 participants, and the +72C SNP was
reported to be in complete linkage with rs1800471, but could not
be identified on dbSNP. [20] None of the 6 studies found any
associations between rs1800468 or rs1800472 and end-stage
CHD. [6,11,13,19,20] In contrast, CHD-associated MI was linked
to the minor T alleles of rs1800469 and rs1800470 by Koch et al.
(2006) (odds ratios 1.14, 95% CI 1.00–1.30, P =0.042) and
Yokata et al. (2000) (odds ratio 3.5, 95% CI 2.0–6.3, P,0.0001)
respectively, although this conflicts with findings from other
authors. [5,6,11,12,13,18,19,20] Similarly, Cambien et al. (1996)
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(odds ratio 1.40, 95% CI 1.02–1.92, P =0.036), however this was
not supported by data generated by subsequent investigations into
this polymorphism. [5,6,12,13,19,20] It is important to note that
Koch et al. (2006) and Yokata et al. (2000) separated their results
by sex, and found positive associations only in the male
populations. [18,19] The association identified by Cambien et al.
(1996) was also restricted to a male population, as this study did
not include female participants. [20].
Quantitative Data Synthesis
The association between reported TGF-b1 SNPs and compli-
cations of CHD was assessed using additive, dominant and
recessive models of inheritance (Table 2 and Table S2). Analyses
revealed no significant association of the TGF-b1 rs1800468 and
rs1800472 under any model, and these SNPs were not further
investigated. Heterogeneity assessments for rs1800469, rs1800470
and rs1800471 demonstrated significant inter-study variation,
particularly for rs1800470, under additive and recessive models
(Table 3 and Table S2), thus data from these models were
disregarded. In contrast, no heterogeneity was observed for
calculations made using the dominant model of inheritance
suggesting that conclusions made applying this algorithm were
relatively robust. Findings from the dominant model of inheritance
were therefore selected for further assessment. Significant positive
associations were observed between CHD complications and the
minor alleles of rs1800469 (OR 1.125, 95% CI 1.016–1.247, P
=0.031), rs1800470 (OR 1.146, 95% CI 1.026–1.279, P =0.021)
and rs1800471 (OR 1.207, 95% CI 1.037–1.406, P =0.021;
Table 2). As expected, odds ratios generated by the current meta-
analysis differed from findings of previous studies (Figure 2).
Funnel plots suggested no publication bias was observed for these
SNPs (Figure S1). Sensitivity analyses confirmed that multiple
studies contributed to the observed significant associations
between rs1800469, rs1800470 and end-stage CHD under a
dominant model of inheritance (Table 4). In contrast, the
significant association between rs1800471 and CHD end points
was only lost if the individual study by Cambien et al. (1996) was
removed. [20].
Discussion
The association between SNPs of the TGF-b1 cytokine and
clinically significant cardiac events was previously unclear due to
conflicting data generated by a range of independent studies. To
clarify this we conducted a meta-analysis of publically available
data, confirming significant associations between the minor alleles
of TGF-b1 rs1800469, rs1800470 and rs1800471 with CHD when
applying a dominant model of inheritance. Odds ratios generated
for these SNPs were relatively low (1.125 – 1.207), as expected for
a multifactorial disease such as CHD.
Odds ratios generated by our meta-analysis for TGF-b1
rs1800469, rs1800470 and rs1800471 are lower than previously
reported, [18,19,20] possibly reflecting the larger, more genetically
diverse population analysed in this study. Odds ratios may also
have been lowered as we assessed patient populations of mixed
gender. Previously Cambien et al. (1996), Yokata et al. (2000) and
Koch et al. (2006) independently identified positive associations
between these SNPs and end-stage CHD in their male recruits
only. [18,19,20] These associations were not observed in cohorts
comprising both male and female subjects. [11,12,13] This
tentatively suggests that these SNPs may be more relevant to
CHD progression in male carriers although this hypothesis could
not be assessed in the current study as sex-specific data were not
provided by all investigators.
Mechanisms underpinning the positive associations of TGF-b1
rs1800649, rs1800470 and rs1800471 with development of end-
stage CHD remain unclear. These SNPs are located within
functional regions of the TGF-b1 gene and it is therefore
plausible to suggest that they may directly impact on TGF-b1
signalling. For example, rs1800469 is situated within the
promoter region of the TGF-b1 gene and has been reported to
alter secretion of TGF-b1 in vitro. [21] Interestingly, Yokota et al.
(2000) reported reduced serum concentrations of TGF-b1 in
subjects carrying the TC or TT genotype rs1800469 compared to
the CC genotype. [18] No significant difference in circulating
TGF-b1 was observed between case (myocardial infarction) or
control recruits of the same genotype, suggesting that altered
circulating levels of TGF-b1 are not the principal cause of CHD
complications in this population. Rs1800470 and rs1800471 are
both located within exons, resulting in amino acid changes of
Leu10Pro and Arg25Pro respectively. Cox et al. (2007) reported that
the proline substitution at codon 10 is associated with higher
circulating concentrations of acid-activatable TGF-b1 and
Figure 1. Flow diagram showing studies included. 45 published
studies assessing the association of TGF-b SNPs and CHD were
identified by searching the MEDLINE database. Appraisal of the
abstracts identified 10 articles eligible for full-text appraisal. From
these, a further 2 articles were excluded, leaving 8 articles for inclusion
in the systematic review. Six of these studies adopted a case-control
design, and data from these were extracted for further assessment in
the meta-analysis.
doi:10.1371/journal.pone.0037878.g001
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PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37878Table 2. Meta-analysis of published associations between TGF-b1 SNPs and complications of CHD.
SNP Population Cases Controls OR* 95% CI p value
rs1800468
, Syrris et al. [13] 655 244 1.246 0.826–1.80 0.294
Cambien et al. [20] 563 629 1.084 0.792–1.482 0.615
Crobu et al. [11] 201 201 0.756 0.434–1.319 0.325
*Combined 1419 1074 1.064 0.846–1.339 0.346
rs1800469
6 Syrris et al. [13] 655 244 1.215 0.905–1.631 0.194
Cambien et al. [20] 563 629 0.967 0.768–1.217 0.776
Koch et al. [19]
{ 3657 1211 1.145 1.005–1.304 0.042
Crobu et al. [11] 201 201 1.322 0.880–1.987 0.179
*Combined 5076 2285 1.125 1.016–1.247 0.031
rs1800470
1 Syrris et al. [13] 655 244 1.226 0.908–1.654 0.183
Cambien et al. [20] 563 629 1.175 0.924–1.465 0.188
Koch et al. [19]
{ 3657 1211 1.193 1.042–1.365 0.01
Crobu et al. [11] 201 201 1.388 0.907–2.123 0.131
Yokota et al. [18]
{ 315 591 0.856 0.629–1.164 0.322
Holweg et al. [12] 144 94 0.909 0.535–1.544 0.724
*Combined 5535 2970 1.146 1.026–1.279 0.021
rs1800471
¤ Syrris et al. [13] 655 244 1.24 0.800–1.923 0.337
Cambien et al. [20] 563 629 1.404 1.022–1.927 0.036
Koch et al. [19]
{ 3657 1211 1.159 0.953–1.409 0.14
Holweg et al. [12] 144 94 0.899 0.438–1.848 0.772
*Combined 5019 2178 1.207 1.037–1.406 0.021
rs1800472u Syrris et al. [13] 655 244 1.796 0.784–4.116 0.166
Cambien et al. [20] 563 629 0.638 0.389–1.044 0.074
Koch et al. [19]
{ 3657 1211 1.033 0.791–1.349 0.812
*Combined 4875 2084 0.978 0.622–1.536 0.397
OR, odds ratio; CI, 95% confidence intervals.
,Rs1800468: promoter, in terms of minor A allele;
6Rs1800469: promoter, in terms of minor T allele;
1Rs1800470: coding sequence, in terms of minor T allele;
¤Rs1800471: coding sequence, in terms of minor C allele; uRs1800472: coding sequence, in terms of minor T allele.
*Combined, indicates meta-analysis data calculated for a Random Effects model, assuming dominant inheritance. Data for additive and recessive models displayed in
Table S1.
{Odds ratio given for combined male and female population, not just male population as provided by author.
{Odds ratio given in terms of minor allele, not major allele as stated in publication.
doi:10.1371/journal.pone.0037878.t002
Table 3. Heterogeneity analysis of combined effect size.
Additive model Dominant Model Recessive Model
SNP Genotype Q df (Q) P I
2 Qd f ( Q ) PI
2 Qd f ( Q ) PI
2
rs1800469 CC – – – – – – – – – – – –
CT 2.351 3 0.503 0.000 2.595 3 0.458 0.000 – – – –
TT 4.017 3 0.260 0.253 4.634 3 0.201 0.353
rs1800470 TT – – – – – – – – – – – –
TC 0.767 5 0.979 0.000 5.532 5 0.354 0.096 - – – –
CC 25.854 5 ,0.001 0.807 31.145 5 ,0.001 0.839
rs1800471 GG – – – – – – – – – – – –
GC 1.870 3 0.600 0.000 1.694 3 0.638 0.000 – – – –
CC 2.747 3 0.432 0.000 2.731 3 0.435 0.000
Q, Cochran Q test; df, degrees of freedom; I
2,I
2 index.
doi:10.1371/journal.pone.0037878.t003
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intracellular trafficking, or increased transcription. Substitution of
proline residues are also likely to alter the chemical properties
and tertiary structure of TGF-b1 protein, potentially interfering
with receptor interactions. However, these effects are yet to be
described.
Limitations
This study has several limitations. Firstly, only 6 published
studies fulfilled our selection criteria, thus the meta-analysis was
restricted to a relatively small patient population primarily
comprising subjects from Western Europe. Importantly, these
studies focused solely on TGF-b1 SNPs and we were therefore
unable to investigate the contribution of TGF-b2 or TGF-b3
polymorphisms to the development of end-stage CHD. Secondly,
we were unable to adjust the meta-analysis to correct for common
cardiovascular risk factors (e.g. gender or smoking) as these were
not uniformly reported in the independent investigations and
could not be easily obtained. This was further complicated by
significant variation in clinical definitions of hypertension and
dyslipidaemia. [13] It is therefore possible that calculated ORs and
P values are over-estimates of the true biological situation. Thirdly,
significant heterogeneity was observed between studies suggesting
that these data could not be investigated using the additive and
recessive models of inheritance. Similarly, we noted significant
inter-study variation in methods employed to screen control
populations. Only 2 of the analysed studies provided a definitive
negative CHD diagnosis in controls via coronary angiography,
[13,19] whereas other studies employed non-specific methodolo-
gies, such as electrocardiography, or a complete lack of screening.
[11,12,18,20] Consequently, there is potential for false negative
diagnoses in some studies, and it is feasible to suggest that control
subjects may not truly represent healthy (CHD-free) individuals.
Finally, data collected from patients presenting with a range of
cardiovascular complications were appraised in this analysis,
thereby assuming that similar pathological mechanisms underpin
distinct CHD endpoints. Subsequently, we are unable to suggest
specific contributions of TGF-b1 SNPs to the development of
discrete events such as myocardial infarction and end stage heart
failure.
The authors attempted to include SNPs related to the TGF-b
genes from previous GWAS in the present meta-analysis. Prior to
data extraction, the Catalogue of Published Genome-Wide
Association Studies (genome.gov) was searched and 16 CHD
GWAS were identified. [23] The full text and supplementary data
of these studies were hand-searched by the primary author. The
Figure 2. Forest plots detailing unadjusted odds ratios and 95% confidence intervals for the association between TGFb1
rs1800469, rs1800470 and rs1800471 with end-stage CHD calculated using the dominant model of inheritance. The dotted line
represents overall odds ratio calculated in the current meta-analysis for each SNP.
doi:10.1371/journal.pone.0037878.g002
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have not been highlighted in recent GWAS focused on the
presence or complications of CHD. The reasons for differences
between findings of candidate gene and genome wide association
studies are currently unexplained. Some possible reasons include:
risk alleles only acting in certain populations due to variation in
other genetic factors or environmental exposure, false discovery,
confounding effects of combining samples and data from very
Table 4. Leave-one-out sensitivity analysis of combined effect size.
Additive model Dominant model Recessive model
SNP Study removed Genotype OR 95% CI P OR 95% CI P OR 95% CI P
rs1800469 Syrris et al. [13] C C – – ––– ––– –
CT 1.105 0.977–1.249 .0.05 1.110 0.978–1.259 .0.05 – – –
TT 1.190 0.890–1.591 .0.05 1.160 0.862–1.562 .0.05
Cambien et al. [20] C C – – ––– ––– –
CT 1.168 1.035–1.319 ,0.05 1.168 1.042–1.310 ,0.05 – – –
TT 1.271 0.917–1.762 .0.05 1.202 0.852–1.697 .0.05
Koch et al. [19] C C – – ––– ––– –
CT 1.052 0.883–1.253 .0.05 1.106 0.918–1.333 .0.05 – – –
TT 1.301 0.922–1.837 .0.05 1.263 0.932–1.712 .0.05
Crobu et al. [11] C C – – ––– ––– –
CT 1.113 0.979–1.266 .0.05 1.113 1.001–1.237 ,0.05 – – –
TT 1.085 0.910–1.294 .0.05 1.027 0.869–1.214 .0.05
rs1800470 Syrris et al. [13] T T – – ––– ––– –
TC 1.149 1.029–1.283 ,0.05 1.123 0.978–1.291 .0.05 – – –
CC 1.028 0.656–1.611 .0.05 0.969 0.625–1.502 .0.05
Cambien et al. [20] T T – – ––– ––– –
TC 1.151 1.027–1.291 ,0.05 1.126 0.968–1.309 .0.05 – – –
CC 1.047 0.639–1.714 .0.05 0.986 0.608–1.601 .0.05
Koch et al. [19] T T – – ––– ––– –
TC 1.119 0.961–1.304 .0.05 1.104 0.936–1.303 .0.05
CC 1.041 0.606–1.788 .0.05 0.985 0.577–1.679 .0.05
Crobu et al. [11] T T – – ––– ––– –
TC 1.156 1.039–1.287 ,0.05 1.127 0.999–1.270 .0.05 – – –
CC 0.950 0.651–1.386 .0.05 0.882 0.615–1.264 .0.05
Yokota et al. [18] T T – – ––– ––– –
TC 1.166 1.044–1.301 ,0.05 1.192 1.074–1.322 ,0.05 – – –
CC 1.298 1.010–1.667 ,0.05 1.210 0.937–1.563 .0.05
Holweg et al. [12] T T – – ––– ––– –
TC 1.158 1.042–1.288 ,0.05 1.156 1.028–1.300 ,0.05 – – –
CC 1.156 0.777–1.719 .0.05 1.076 0.726–1.595 .0.05
rs1800471 Syrris et al. [13] G G – – ––– ––– –
GC 1.182 1.002–1.395 ,0.05 1.203 1.023–1.415 ,0.05 – – –
CC 1.828 0.674–4.954 .0.05 1.787 0.663–4.821 .0.05
Cambien et al. [20] G G – – ––– ––– –
GC 1.144 0.959–1.366 .0.05 1.154 0.970–1.373 .0.05 – – –
CC 1.224 0.554–2.701 .0.05 1.205 0.546–2.659 .0.05
Koch et al. [19] G G – – ––– ––– –
GC 1.221 0.955–1.561 .0.05 1.285 1.009–1.637 ,0.05 – – –
CC 3.667 1.033–13.012 ,0.05 3.576 1.008–12.680 ,0.05
Holweg et al. [12] G G – – ––– ––– –
GC 1.210 1.032–1.418 ,0.05 1.224 1.048–1.430 ,0.05 – – –
CC 1.553 0.676–3.570 .0.05 1.490 0.669–3.320 .0.05
OR, odds ratio; 95% CI, 95% confidence intervals. Analysis was performed using a random effects model.
doi:10.1371/journal.pone.0037878.t004
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PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e37878different studies where information is collected under different
definitions, variation in demographic profile of control popula-
tions, and heterogeneity of data collection methods across studies.
Conclusion
In conclusion, we confirm significant positive associations
between the TGF-b1 SNPs rs1800469, rs1800470 and rs1800471
and complications of CHD. Further work is required to determine
the clinical relevance of these findings.
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